Journal article
Defining pre-symptomatic amyotrophic lateral sclerosis
- Abstract:
-
Successful treatment of neurodegenerative disease may hinge on early therapeutic intervention. This requires an understanding of early/pre-symptomatic disease, a need that is underscored by advances in antisense oligonucleotide, and viral-vector-based gene therapies. In amyotrophic lateral sclerosis (ALS), the study of pre-symptomatic disease requires a cohesive conceptual framework for describing this phase of disease. Informed by the literature in other neurodegenerative diseases and extens...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 671.1KB)
-
- Publisher copy:
- 10.1080/21678421.2019.1587634
Authors
Bibliographic Details
- Publisher:
- Taylor and Francis Publisher's website
- Journal:
- Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal website
- Volume:
- 20
- Issue:
- 5-6
- Pages:
- 303-309
- Publication date:
- 2019-03-20
- Acceptance date:
- 2019-02-17
- DOI:
- EISSN:
-
2167-9223
- ISSN:
-
2167-8421
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:974353
- UUID:
-
uuid:676c7533-c635-4bcb-8321-6f02f2225c65
- Local pid:
- pubs:974353
- Source identifiers:
-
974353
- Deposit date:
- 2019-02-18
Terms of use
- Copyright holder:
- World Federation of Nuerology
- Copyright date:
- 2019
- Rights statement:
- © 2019 World Federation of Neurology on behalf of the Research Group on Motor Neuron Diseases
- Notes:
-
This is the accepted manuscript version of the article. The final version is available from Taylor and Francis at https://doi.org/10.1080/21678421.2019.1587634
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record